Argos Nears Phase III Results For Precision Cancer Immunotherapy

With pivotal data expected in 2017 in metastatic kidney cancer, Argos hopes its drug will bridge the hot points of immuno-oncology and personalized medicine with a drug that extract’s RNA from a patient’s tumor and primes the dendritic cells to teach the immune system how to kill the cancer.

T-cell

After 17 years of work, Argos Therapeutics Inc. hopes to present a breakthrough in 2017 with Phase III data for its lead candidate in metastatic renal cell carcinoma – what CEO Jeff Abbey says will be precision immunotherapy that eventually could be applied broadly across the oncology space.

During an investor day presentation Dec. 7, the Durham, N.C.-based biotech outlined the clinical development process for AGS-003 (now called...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Anticancer

More from Therapeutic Category